Zhejiang Xianju Pharmaceutical Co.,Ltd.

SZSE:002332 Rapport sur les actions

Capitalisation boursière : CN¥12.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Zhejiang Xianju PharmaceuticalLtd Résultats passés

Passé contrôle des critères 2/6

Zhejiang Xianju PharmaceuticalLtd has been growing earnings at an average annual rate of 13.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3.7% per year. Zhejiang Xianju PharmaceuticalLtd's return on equity is 9.9%, and it has net margins of 13.8%.

Informations clés

13.3%

Taux de croissance des bénéfices

11.1%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie10.9%
Taux de croissance des recettes3.7%
Rendement des fonds propres9.9%
Marge nette13.8%
Prochaine mise à jour des résultats27 Aug 2024

Mises à jour récentes des performances passées

Recent updates

Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Will Pay A Dividend Of CN¥0.30

Jun 02
Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Will Pay A Dividend Of CN¥0.30

Estimating The Fair Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

Apr 15
Estimating The Fair Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

There Is A Reason Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Price Is Undemanding

Mar 05
There Is A Reason Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Price Is Undemanding

Ventilation des recettes et des dépenses

Comment Zhejiang Xianju PharmaceuticalLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

SZSE:002332 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Mar 244,2045811,307288
31 Dec 234,1235631,264261
30 Sep 234,1646921,289255
31 Mar 234,2887551,443251
01 Jan 234,3807491,536267
30 Sep 224,4936891,571237
30 Jun 224,4426761,597241
31 Mar 224,4056361,588249
01 Jan 224,3576191,560243
30 Sep 214,4026051,478232
30 Jun 214,3915731,472232
31 Mar 214,2765481,418232
31 Dec 204,0195051,335208
30 Sep 203,8734781,381228
30 Jun 203,6204421,307215
31 Mar 203,6184201,363210
31 Dec 193,7094101,430205
30 Sep 193,7413811,503169
30 Jun 193,7233521,497161
31 Mar 193,6283191,483146
31 Dec 183,6223011,474143
30 Sep 183,5142771,421124
30 Jun 183,3372491,313135
31 Mar 183,1162311,227107
31 Dec 172,8532071,13388
30 Sep 172,6711871,08847
30 Jun 172,5721681,0960
31 Mar 172,5471491,0890
31 Dec 162,5041461,0450
30 Sep 162,4571359620
30 Jun 162,5041239450
31 Mar 162,4411089000
31 Dec 152,4801078770
30 Sep 152,466888460
30 Jun 152,461718510
31 Mar 152,473608260
31 Dec 142,471577960
30 Sep 142,408458090
30 Jun 142,370387270
31 Mar 142,373516710
31 Dec 132,315616550
30 Sep 132,326786410

Des revenus de qualité: 002332 has high quality earnings.

Augmentation de la marge bénéficiaire: 002332's current net profit margins (13.8%) are lower than last year (17.6%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: 002332's earnings have grown by 13.3% per year over the past 5 years.

Accélération de la croissance: 002332's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: 002332 had negative earnings growth (-23%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).

Rendement des fonds propres

ROE élevé: 002332's Return on Equity (9.9%) is considered low.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y